How Investors Are Reacting To Bristol-Myers Squibb (BMY) Phase I Lung Cancer Data and FDA Breakthrough Designation

• SystImmune Inc. and Bristol Myers Squibb recently presented promising safety and efficacy data from the phase I US-Lung-101 study of iza-bren, an EGFR x HER3 bispecific antibody-drug conjugate, at the European Society for Medical Oncology Congress 2025 following its FDA breakthrough therapy designation for previously treated EGFR-mutated NSCLC.
• This announcement highlights Bristol-Myers Squibb's expanding presence in advanced oncology pipelines and its ongoing collaboration efforts to address areas of significant unmet medical need.
• We'll explore how the encouraging phase I results for iza-bren could influence Bristol-Myers Squibb's investment narrative and future growth prospects.

These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Bristol-Myers Squibb Investment Narrative Recap

To invest in Bristol-Myers Squibb, you need to believe in the company's ability to deliver new therapies from its innovative pipeline fast enough to offset looming revenue loss from upcoming patent expirations. The recent positive phase I data for iza-bren in advanced lung cancer, announced jointly with SystImmune Inc., is a clear signal of ongoing pipeline progress but does not fundamentally change the short-term catalyst, which remains successful new drug launches to mitigate revenue concentration risk, nor does it materially reduce the biggest current risk, exposure to patent cliffs and generic competition.

Among recent announcements, the FDA's breakthrough therapy designation for iza-bren in previously treated EGFR-mutated NSCLC stands out for its potential to accelerate a new first-in-class treatment to market. This directly ties into current catalysts by increasing confidence in Bristol-Myers Squibb's capability to replenish its revenue base through late-stage innovation, though the long-term outcome will hinge on advancing these candidates through later-stage trials and commercialization.

In contrast, investors should be aware that even with pipeline wins, concentration risk around upcoming patent expiries remains a key challenge...

Read the full narrative on Bristol-Myers Squibb (it's free!)

Bristol-Myers Squibb’s outlook anticipates $41.3 billion in revenue and $9.2 billion in earnings by 2028. This forecast is based on revenue declining at a rate of 4.7% per year and earnings increasing by $4.2 billion from the current $5.0 billion.

Uncover how Bristol-Myers Squibb's forecasts yield a $53.00 fair value, a 19% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members provided 11 independent fair value estimates for Bristol-Myers Squibb, ranging from US$50.00 to US$132.72 per share. Despite pipeline progress, scrutiny around patent cliffs could shape outcomes for revenue and valuation differently, so consider how diverse these viewpoints can be before you make up your mind.

Explore 11 other fair value estimates on Bristol-Myers Squibb - why the stock might be worth just $50.00!

Build Your Own Bristol-Myers Squibb Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Bristol-Myers Squibb research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Bristol-Myers Squibb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bristol-Myers Squibb's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• We've found 17 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com